Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $11.75

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $11.75.

RGLS has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, July 16th. StockNews.com assumed coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They issued a “sell” rating for the company. Finally, Canaccord Genuity Group boosted their price objective on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RGLS. Victory Capital Management Inc. boosted its position in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after buying an additional 38,529 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Regulus Therapeutics during the second quarter worth about $352,000. Opaleye Management Inc. purchased a new stake in shares of Regulus Therapeutics in the first quarter valued at about $490,000. Vanguard Group Inc. grew its position in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares during the last quarter. Finally, CVI Holdings LLC purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth approximately $4,050,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Up 1.1 %

Shares of NASDAQ:RGLS opened at $1.78 on Friday. The company has a market cap of $116.54 million, a price-to-earnings ratio of -1.22 and a beta of 1.62. Regulus Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The firm’s 50-day simple moving average is $2.02 and its 200-day simple moving average is $1.98.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.14). On average, research analysts forecast that Regulus Therapeutics will post -0.59 EPS for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.